Summary
Signal counts
Assets tracked: 5
Watchlist assets: 5
Registry stop assets: 0
Sponsor overview
Chinese PLA General Hospital
Public clinical-program risk signals across linked oncology Phase 2 assets for this sponsor.
Evidence links
Public sources
https://clinicaltrials.gov/study/NCT04765462 | https://clinicaltrials.gov/study/NCT05554939 | https://clinicaltrials.gov/study/NCT05631912 | https://clinicaltrials.gov/study/NCT02159820 | https://clinicaltrials.gov/study/NCT02135822
Assets
Linked programs
- Allogeneic γδ T cells: Timeline Staleness Signal (4/5)
- Allogenic CD19 CAR-γδT cell: Operational Burden Signal (2/5)
- Autologous CD19-STAR-T cell: Timeline Staleness Signal (4/5)
- Decitabine (DTC Arm): Timeline Staleness Signal (4/5)
- nanoparticle albumin-bound paclitaxel: Timeline Staleness Signal (3/5)